GROUNDBREAKING STUDY LAUNCHES

"Intermountain launches groundbreaking study using the PreTRM test to prevent preterm birth." Read more here

DOCTORS SPEAK OUT

"Women want good information. If a test predicts that they might have a preterm birth, they want to know."

PROTEOMIC INNOVATION

PreTRM Test Featured in Top-Tiered Scientific Journal as Example of Proteomic Test That Advances Patient Care. Read More

DOCTORS SPEAK OUT

"The value of the PreTRM test cannot be overestimated. We continue to deal with the vast majority of women who eventually go into preterm labor and deliver early with having absolutely no identifiable risk factors." Watch Dr. Shulman's video here

PROTEOMIC INNOVATION

“We developed a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.” Dr. Greg Critchfield, CEO

DOCTORS SPEAK OUT

"With 1 in 10 women in the United States delivering prematurely, I believe every woman is an excellent candidate for the PreTRM test." Watch Dr. Mandel's video here

News

Sera Prognostics to Present at Baird’s 2020 Global Health Care Conference

September 9, 2020- Sera will be presenting at the upcoming Baird 2020 Global Health Care Conference. A virtual conference, Sera’s presentation will take place on Thursday, September 10 at 10:50 a.m. ET. Read More >

Sera Prognostics Appoints Thomas J. Garite, M.D. as Vice President of Clinical Sciences

June 24, 2020 - Sera announced the appointment Thomas J. Garite, M.D. as Vice President of Clinical Sciences. - Dr. Garite will support clinical development and operations as Sera transitions from clinical to commercial-stage company. Read More >

Publication Demonstrates Ability of Sera Prognostics’ PreTRM® Biomarker Test as a Predictor of Adverse Pregnancy Outcomes

May 20, 2020 - Sera Prognostics, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine. Read More >

WHO WE ARE

PROVIDING INDIVIDUALIZED RISK ASSESSMENT TO PREDICT AND MANAGE PREMATURE BIRTH, PREECLAMPSIA, AND OTHER PREGNANCY COMPLICATIONS

Sera Prognostics is dedicated to improve the lives of women and babies through individualized prenatal care.  Sera’s strategy is to deliver pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women.  Our first test, the PreTRM® Test, focuses on the early prediction of preterm birth risk, one of the most serious pregnancy complications which affects almost one in ten pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications helps pregnant women and their doctors better understand risks and proactively address risks of adverse pregnancy outcomes.  Learn about the PreTRM® Test for Risk Management.